ALK fusion gene-positive lung cancer.
Conditions
Interventions
None listed
Sponsors
Specified Nonprofit Corporation North East Japan Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who started treatment with Alectinib for advanced or recurrent NSCLC with ALK fusion gene positivity between September 1, 2014 and December 31, 2022.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of ALK-TKI administration prior to alectinib administration (patients with a history of chemotherapy other than ALK-TKI are eligible for inclusion). 2. Patients with meningeal carcinomatosis prior to alectinib administration. 3. Patients who refused to participate in this study based on the informed consent document. 4. Patients whom the principal investigator or co-investigator deemed unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence and details of local treatment for brain metastases, and survival outcomes (overall survival [OS], progression-free survival [PFS], and central nervous system progression-free survival [CNS-PFS]). The study includes calculation of the proportion of patients who experienced progression or newly developed brain metastases during alectinib treatment; assessment of the presence and details of local treatment for brain metastases; evaluation of survival outcomes (overall survival [OS], progression-free survival [PFS], and central nervous system progression-free survival [CNS-PFS]); analysis of survival in patients who continued alectinib after receiving additional local treatment for progressive or newly developed brain metastases; and investigation of the impact of new-onset brain metastases on prognosis (OS and PFS). | — |
Countries
Japan
Contacts
Public ContactSusumu Takeuchi
Nippon Medical School Hospital Department of Pulmonary Medicine and Oncology
Outcome results
None listed